Efficacy and safety of obinutuzumab in active lupus nephritis

Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided sig nificantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving standard therapy. METHODS In a phase 3, randomized, controlled trial, we assigned adults with biopsy-prove...

Full description

Autores:

Furie, R.A.
Rovin, B.H.
Garg, J.P.
Santiago, M.B.
Aroca Martínez, G.
Zuta Santillán, A.E.
Álvarez, D.
Navarro Sandoval, C.
Lila, A.M.
Tumlin, J.A.
Saxena, A.
Irazoque Palazuelos, F.
Raghu, H.
Yoo, B.
Hassan, I.
Martins, E.
Sehgal, H.
Kirchner, P.
Ross Terres, J.
Omachi, T.A.
Schindler, T.
Pendergraft, W.F.
Malvar, A.

Tipo de recurso:

Fecha de publicación:

2025

Institución:

Universidad Simón Bolívar

Repositorio:

Repositorio Digital USB

Idioma:

eng

OAI Identifier:

oai:bonga.unisimon.edu.co:20.500.12442/16252

Acceso en línea:

https://hdl.handle.net/20.500.12442/16252
https://www.nejm.org/doi/full/10.1056/NEJMoa2410965

Palabra clave:

Rights

closedAccess

License

Attribution-NonCommercial-NoDerivs 3.0 United States